Skip to content

Advertisement

Open Access

Correction to: Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol

  • Marie Lange1, 2, 3,
  • Heidi Laviec4,
  • Hélène Castel3, 5,
  • Natacha Heutte1, 2,
  • Alexandra Leconte2,
  • Isabelle Léger1, 3, 6, 7,
  • Bénédicte Giffard3, 8,
  • Aurélie Capel2,
  • Martine Dubois3, 5,
  • Bénédicte Clarisse2,
  • Elodie Coquan2, 4,
  • Frédéric Di Fiore9, 10,
  • Sophie Gouérant9, 10,
  • Philippe Bartélémy11,
  • Laure Pierard11,
  • Karim Fizazi12 and
  • Florence Joly1, 2, 3, 13Email author
BMC Cancer201818:110

https://doi.org/10.1186/s12885-017-3764-9

Received: 9 November 2017

Accepted: 9 November 2017

Published: 30 January 2018

The original article was published in BMC Cancer 2017 17:549

Correction

After publication of the original article [1] the authors found that Table 2 had been formatted incorrectly, meaning that some rows in the Table did not display the correct information.

An updated version of Table 2 is included with this Correction.
Table 2

Used cognitive tests, questionnaires and biological tests

MoCA Montreal Cognitive Assessment, WAIS Wechsler Adult Intelligence Scale, VOSP Visual Object and Space Perception Battery, fNART French National Adult Reading Test, ISI Insomnia Severity Index, VAS Visual Analog Scale, ADL Activities of Daily Living, IADL Instrumental Activities of Daily Living, MNA Mini-Nutritional Assessment

aCognitive assessment will be performed by neuropsychologists

bFor group of interest patients: before the start of the treatment or within 15 days after the start of treatment by abiraterone acetate or enzalutamide

cHad to be ≤3 on the 0–10 pain VAS scale to meet with inclusion pain criteria

dGeriatric assessment will be performed by a study nurse specialized in geriatric

eAdherence evaluation will be performed only in group of interest patients

fAt each time: CBC, platelets, albumin, CRP, prealbumin, iron, ferritin, transferrin, creatinin, sodium, potassium, ALT, AST, GGT, ALP, total bilirubin, TSH, T4, testosterone. At inclusion only: cortisol (at 8 h AM, fasting)

g1 EDTA (5 ml), 1 dry tube with gel (5 ml) and 1 dry tube without gel (5 ml)

The original article has also been updated.

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
INSERM, U1086 ANTICIPE, Normandie University, UNICAEN, Caen, France
(2)
Clinical Research Department, Centre François Baclesse, Caen, France
(3)
Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, Caen, France
(4)
Medical Oncology Department, Centre François Baclesse, Caen, France
(5)
Laboratory of Neuronal and Neuroendocrine Differentiation and Communication, Normandie University, UNIROUEN, INSERM, DC2N, Rouen, France
(6)
UPO, Gustave Roussy, Villejuif, France
(7)
NeuroHIV Rehabilitation Unit, Bicêtre University Hospital, Le Kremlin Bicêtre, France
(8)
Normandie University, UNICAEN, EPHE Paris, INSERM, U1077, Caen, France
(9)
Medical Oncology Department, Centre Henri-Becquerel, Rouen, France
(10)
Digestive and Urology Oncology Unit, Rouen University Hospital, Rouen, France
(11)
Medical Oncology and Hematology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
(12)
Medical Oncology Department, Gustave Roussy, Villejuif, France
(13)
Medical Oncology Department, CHU de Caen, Caen, France

Reference

  1. Lange M, Laviec H, Castel H, Heutte N, Leconte A, Léger I, Giffard B, Capel A, Dubois M, Clarisse B, Coquan E, Di Fiore F, Gouérant S, Bartélémy P, Pierard L, Karim F, Joly F. Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol. BMC Cancer. 2017;17:549. https://doi.org/10.1186/s12885-017-3534-8.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement